SPS
YMAB

Susquehanna Portfolio Strategies’s Y-mAbs Therapeutics YMAB Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,456
Closed -$105K – 976
2023
Q4 		$105K Buy
+15,456
New +$89.4K ﹤0.01% 974

Other funds holding YMAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna Portfolio Strategies's YMAB Position: Q1 2024 in Review

Susquehanna Portfolio Strategies sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 15,456 shares — an estimated $105K sold.

Susquehanna Portfolio Strategies first reported a position in YMAB in Q4 2023 and held it in 1 quarter. The position peaked at $105K in Q4 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Susquehanna Portfolio Strategies reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 15,456 Y-mAbs Therapeutics shares in Q1 2024, an estimated $105K.
  • Susquehanna Portfolio Strategies first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 1 quarter.
  • Susquehanna Portfolio Strategies's Y-mAbs Therapeutics position peaked at $105K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2024, filed 7 May 2024.